Myocardial structural and functional changes in patients with liver cirrhosis awaiting liver transplantation: a comprehensive cardiovascular magnetic resonance and echocardiographic study

Hyue Mee Kim 1,2, Hyung-Kwan Kim 1*, Jeong-Hoon Lee 3*, Yun Bin Lee 3, Eun-Ah Park 4, Jun-Bean Park 1, Seung-Pyo Lee 1, Yoon Jun Kim 3, Yong-Jin Kim 1, Jung-Hwan Yoon 3 and Dae-Won Sohn 1

Abstract

Background: Cardiac dysfunction is increasingly recognized in patients with liver cirrhosis. Nevertheless, the presence or absence of structural alterations such as diffuse myocardial fibrosis remains unclear. We aimed to investigate myocardial structural changes in cirrhosis, and explore left ventricular (LV) structural and functional changes induced by liver transplantation.

Methods: This study included 33 cirrhosis patients listed for transplantation and 20 healthy controls. Patients underwent speckle-tracking echocardiography and cardiovascular magnetic resonance (CMR) with extracellular volume fraction (ECV) quantification at baseline (n = 33) and 1 year after transplantation (n = 19).

(Continued on next page)
Results: CMR-based LV ejection fraction (CMR$_{LV-EF}$) and echocardiographic LV global longitudinal strain (LV-GLS) demonstrated hyper-contractile LV in cirrhosis patients (CMR$_{LV-EF}$: 67.8 ± 6.9% in cirrhosis vs 63.4 ± 6.4% in healthy controls, $P = 0.027$; echocardiographic GLS: −24.2 ± 2.7% in cirrhosis vs −18.6 ± 2.2% in healthy controls, $P < 0.001$). No significant differences in LV size, wall thickness, mass index, and diastolic function between cirrhosis patients and healthy controls were seen (all $P > 0.1$). Only one of the cirrhosis patients showed late gadolinium enhancement. However, cirrhosis patients showed a higher ECV (31.6 ± 5.1% vs 25.4 ± 1.9%, $P < 0.001$) than healthy controls. ECV showed a positive correlation with Child-Pugh score ($r = 0.564$, $P = 0.001$). Electrocardiogram-based corrected QT interval was prolonged in cirrhosis ($P < 0.001$). One-year post-transplantation, echocardiographic LV-GLS (from −24.9 ± 2.4% to −20.6 ± 3.4%, $P < 0.001$) and ECV (from 30.9 ± 4.5% to 25.4 ± 2.6%, $P = 0.001$) moved to the normal ranges. Corrected QT interval decreased after transplantation (from 475 ± 41 to 429 ± 30 msec, $P = 0.001$).

Conclusions: Myocardial extracellular volume expansion with augmented resting LV systolic function was characteristic of cirrhotic cardiomyopathy, which normalizes 1-year post-transplantation. Thus, myocardial extracellular expansion represents a structural component of myocardial changes in cirrhosis.

Keywords: Extracellular volume fraction, Cardiovascular magnetic resonance, Left ventricle, Global longitudinal strain, Cirrhosis.

Background
Liver cirrhosis is associated with chronic dysfunction in the cardiovascular system [1–4]. Cardiac dysfunction is usually subclinical at rest, but can be clinically manifest, especially when rapid blood volume shift occurs, for example in transjugular intrahepatic portosystemic shunt or liver transplantation, which subsequently contributes to cardiovascular complications [5–7]. This cardiac condition in cirrhosis is referred to as cirrhotic cardiomyopathy. This unique cardiomyopathy is characterized by blunted contractile response to stress stimuli, diastolic dysfunction, and electrophysiological abnormalities in the absence of gross cardiac diseases [1–4]. Since myocardial changes observed in cirrhosis were mostly based on echocardiography, earlier studies mainly focused on functional and hemodynamic changes without co-demonstration of anatomical changes. Thus, myocardial structural changes in cirrhosis remain largely unclear, although diffuse myocardial fibrosis (DMF) was suggested, mostly in patients with alcoholic cirrhosis [8, 9]. Therefore, whether functional changes on echocardiography are secondary to myocardial structural changes, or are simply collateral phenomena resulting from cirrhosis-induced hemodynamic alteration without myocardial structural changes remains to be established.

Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) is a widely utilized non-invasive imaging protocol for myocardial tissue characterization. However, a drawback of LGE is its insufficient sensitivity in detecting reversible, early stage diffuse interstitial fibrosis or DMF [10, 11]. Recently, extracellular volume fraction (ECV) quantification by CMR T1 mapping technique has been introduced to evaluate DMF in vivo. Previous studies demonstrated that ECV reliably reflect the degree of DMF and, more importantly, is associated with prognosis in various cardiac diseases [12–14]. Thus, in this study, we hypothesized that myocardium in liver cirrhosis has structural alterations such as DMF, which could be effectively addressed by CMR. We also attempted to relate the structural changes to functional or hemodynamic changes on echocardiography. Finally, we evaluated whether these changes could be reversed by liver transplantation.

Methods
Study population
From March 2016 to December 2017, 36 patients with liver cirrhosis of various etiologies who were listed on the transplant waitlist were prospectively enrolled, of whom three (8.3%) were excluded as they failed to undergo CMR due to acute clinical deterioration. All included patients had been referred to the cardiology department for cardiac evaluation before transplantation. Liver cirrhosis was confirmed based on clinical, laboratory, and ultrasonographic findings [15–17]. Patients with any of the following were systematically excluded: aged < 18 years, decreased kidney function (estimated glomerular filtration rate < 30 mL/min/1.73 m$^2$), documented history of cardiovascular diseases including coronary artery disease, and other forms of myocardial disease, and acute liver failure without cirrhosis. All patients underwent computed tomographic coronary angiography or invasive coronary angiography as a routine preoperative assessment. The absence of a significant coronary artery disease (> 50% luminal stenosis) was verified. Electrocardiogram (ECG), transthoracic echocardiography, and CMR were performed at baseline ($n = 33$) and repeated at 1 year after transplant ($n = 19$). Clinical data on baseline characteristics were collected. Liver cirrhosis severity was categorized according to the Child-Pugh score. For comparison, 20 subjects without
any cardiovascular disease or cardiovascular disease risk factors were included as healthy controls. This study was conducted according to the principles of the Declaration of Helsinki and approved by the Institutional Review Board of our institution. Written informed consent was obtained from all participants.

**Transsthoracic echocardiography and ECG**

Echocardiographic and ECG examinations were conducted as part of the preoperative cardiac evaluation. Echocardiographic data were obtained with commercially available equipments (Vivid 7, General Electric Healthcare, Horten, Norway; E9, Philips Healthcare, Andover, Massachusetts, USA; Acuson SC2000, Siemens Medical Solutions, Mountain View, California, USA). Conventional echocardiographic parameters were measured by experienced sonographers. Left ventricular (LV) ejection fraction (LVEF) was calculated in accordance with the American Society of Echocardiography guideline [18]. To assess LV diastolic function, the transmitral inflow peak early (E) and late (A) diastolic velocities, early septal mitral annular diastolic velocity (e'), left atrial (LA) volume index (LAVI), and peak tricuspid regurgitation velocity were recorded. LA volumes were measured using biplane area-length method at the end-diastolic volume and LA volume index (LAVI) was calculated as LA volume divided by body surface area. LV diastolic function was graded based on the 2016 recommendation [19]. Contrast echocardiography using agitated saline was performed through a left antecubital intravenous line to assess the presence or absence of intrapulmonary shunt. Intrapulmonary shunt was confirmed when bubbles were visualized in the LA and/or LV > 3 beats after its appearance in the right atrium. Data on the LV global longitudinal strain (GLS) and global circumferential strain (GCS) were acquired using two-dimensional speckle-tracking echocardiography based on the guideline [20, 21]. Speckle-tracking echocardiography was used to assess strain values because it has been already incorporated into the daily clinical practice and is now the widely available technique of choice for the assessment of LV strain [20, 21]. LV GLS and GCS measurement and analyses were performed using commercially available software (TomTec, Image Arena 4.6, Munich, Germany).

On ECG QT' interval was measured from the start of the Q wave to the end of the T-wave in lead II. To adjust for the heart rate, corrected QT (QTc) interval was calculated by dividing the QT interval by the square root of the R-R interval.

**CMR**

CMR was performed using a 3 T CMR system (MAGNETOM Skyra; Siemens Healthineers, Erlangen, Germany) equipped with six-channel phased-array coils [22]. After acquiring scout images for localization, balanced steady-state free precession cine images were obtained during breath-holding. To include the entire LV volume, LV short-axis images (6-mm thickness with 4-mm intersection gap) were acquired at 10-mm intervals from the base to apex using retrospective ECG gating with the following parameters: repetition time /echo time, 2.8–3.2 msec/1.4–1.6 msec; flip angle, 80°; temporal resolution, 42 msec; field of view, 240 × 300 mm; and matrix, 256 × 150. LV end-diastolic volume (EDV), end-systolic volume (ESV) volumes, and LVEF were measured from the cine images. LV stroke volume, cardiac index and mass index were subsequently calculated.

ECV calculation was performed as follows. After acquiring cine images, a mid-ventricular short-axis section at the papillary muscle level was obtained using the modified Look-Locker inversion-recovery sequence, with three images in the first two Look-Locker segments and five images for the third inversion (the “3–3-5” standard protocol) [23]. Finally, 11 images acquired in 17 heartbeats were obtained, and in-line motion correction and map generation were performed. The following readout parameters were used: section thickness, 6 mm; 2.5/1.1; 6/8 partial Fourier acquisition; field-of-view, 240 × 300 mm; and matrix, 192 × 125. Region of interest was drawn manually at the mid-ventricular septum and LV blood pool on pre- and post-contrast T1 mapping images to measure the ECV. Care was taken to draw the region-of-interest on the compact myocardium and to not include the border of the myocardium because it shows gradual changes in T1 values due to both partial volume averaging artifact and registration error, even after motion correction. One radiologist (E-A Park, with > 10 years of CMR experience) performed all measurements, and myocardial T1 could be measured reliably with one large region of interest on all images. Intra- and interobserver variability was previously reported at our institution for this measurement [12]. ECV was estimated as follows: ECV = (1 − hematocrit) × [1/T1 myocardium post − 1/T1 myocardium pre]/[1/T1 blood post − 1/T1 blood pre] [24].

To evaluate irreversible myocardial fibrosis, the presence or absence of LGE was assessed. LGE images were acquired 10 min after intravenous gadolinium administration (0.2 mmol/kg Magnevist; Schering, Berlin, Germany), immediately followed by 20 mL saline flush. The protocol for obtaining LGE images was as follows: slice thickness, 6 mm; interslice gap, 4 mm; TR, 9.1 msec; TE, 42 msec; flip angle, 13 degrees; and in-plane resolution, 1.4 × 1.9 mm. LGE images from the same image planes as those in the cine images were acquired using inversion recovery segmented spoiled-gradient echo and phase-sensitive inversion recovery sequences. The most appropriate inversion time was set to null the normal myocardium, which was typically between 250 and 300 msec, in both pre- and
post-transplant CMR examinations. LGE CMR images were analyzed by an experienced radiologist (E-A Park), who was blinded to the patients’ information.

At the last stage of this study, myocardial T2 mapping data was acquired in 6 patients using adiabatic T2-prepared fast low-angle shot (FLASH) technique. Three single-shot FLASH images with different T2 preparation times were acquired as follow: echo time (ms): 0, 30, 55 respectively; slice thickness 6 mm; TR, 2.4 msec; TE, 1.0 msec; flip angle, 12 degrees; receiver bandwidth 1184 Hz/pixel; field of view, 288 × 360 mm; and matrix, 144 × 192.

Statistical analysis
Baseline characteristics are described as number and percentages for categorical variables, and mean ± standard deviation for continuous variables. Patient characteristics were compared between groups using a chi-square or Fisher’s exact test for categorical variables, and Student’s t test or Mann-Whitney U test for continuous variables, as appropriate. Changes in echocardiographic, ECG, and CMR parameters between pre- and post-transplant were compared using paired t-test or Wilcoxon signed rank test. Pearson’s correlation coefficient was used to evaluate the relationship between the relevant parameters and Child-Pugh score. A partial correlation analysis between ECV and Child-Pugh score was performed while controlling for cardiac index. All statistical analyses were performed using SPSS (v22.0 Statistical Package for the Social Sciences, International Business Machines, Inc., Armonk, New York, USA). A P-value < 0.05 was considered statistically significant.

Results
Baseline characteristics
A total of 33 patients were analyzed in the final analysis. The patients’ baseline characteristics are summarized in Table 1. Mean age of cirrhosis patients was 56.3 ± 9.9 years and 25 (75.8%) were men. The etiology of cirrhosis was viral in 20 patients (60.6%), alcoholic in 9 (27.3%), and autoimmune hepatitis in 2 (6.1%). Most patients (n = 23, 69.7%) were in Child-Pugh class C and their heart rate was higher than that of patients with Child-Pugh class A/B (P = 0.002). There were no significant differences in the prevalence of hypertension and diabetes mellitus and in the levels of hemoglobin and creatinine between the Child-Pugh class A/B and Child-Pugh class C groups. No significant difference in cardiovascular medications at the time of CMR except for beta-blockers was noted.

Echocardiographic and ECG parameters in cirrhosis
Comparisons of echocardiographic and ECG parameters are shown in Table 2. No significant differences in LV size, LV wall thickness, and Doppler transmitral inflow patterns were found between the healthy controls (65.0 ± 14.8 years; men, 11 (55%)) and cirrhosis patients were observed. Notably, LVEF, a conventional index for LV systolic function, was significantly higher in cirrhosis patients than in normal controls (P = 0.049), indicating a hyper-contractile state in cirrhosis. Resting hyper-contractile state in cirrhosis was corroborated by a significant augmentation in GLS (−24.2 ± 2.7% in cirrhosis vs −18.6 ± 2.2% in the healthy controls, P < 0.001). LAVI and E/e’ ratio were significantly higher in cirrhosis patients than in the normal controls, suggesting impaired LV diastolic function in cirrhosis patients. No significant difference in E/A ratio and deceleration time was found. LV diastolic function in cirrhosis patients could not be classified into one category in 15 patients (45.5%) when the 2016 guideline was applied [19]. In addition, the significant overlap of LA dimension, LAVI and even E/e’ ratio between cirrhosis patients and healthy controls were observed (Fig. 1a, b, and c). Estimated pulmonary artery systolic pressure was significantly higher in patients with Child-Pugh class C than in patients with Child-Pugh class A/B (P = 0.040). As expected, QTc interval was significantly prolonged in cirrhosis patients (P < 0.001). Most ECG and echocardiographic parameters between Child-Pugh class A/B and Child-Pugh class C showed no statistical differences. A significant positive linear correlation was observed between QTc interval and Child-Pugh score (r = 0.388, P = 0.025).

CMR in cirrhosis patients
CMR-based hemodynamic parameters are shown in Table 3. LVEF was significantly higher in cirrhosis patients (P = 0.027), mainly driven by a larger EDV, rather than by a smaller ESV. Moreover, LV stroke volume (99.5 ± 29.3 vs 85.2 ± 15.1 mL, P = 0.025) and cardiac index (4.3 ± 1.1 vs 3.3 ± 0.7 L/min/m2, P = 0.002) were greater in cirrhosis patients, again supporting hyper-dynamic circulation in cirrhosis [2]. No differences in hemodynamic parameters between Child-Pugh class A/B and class C groups were found, although cardiac index tended to higher in Child-Pugh class C group (P = 0.073). With Child- Pugh score as a continuous variable, a positive trend in relation to cardiac index was observed (r = 0.337, P = 0.06). There were no significant differences in terms of LV mass index and LV mass/LV EDV ratio between cirrhosis patients and the healthy control group.

Focal subendocardial LGE was detected at the mid-anterior segment in one cirrhosis patient, whose coronary arteries were normal on invasive coronary angiography. No LGE was found in the healthy controls. Native T1 value of myocardium was significantly longer in patients with cirrhosis compared with healthy subjects (P = 0.001; Table 3). However, there was no statistically significant correlation between Child-Pugh score (as a
Continuous variable) and native T1 value in cirrhosis ($P = 0.87$). Cirrhosis patients had a significantly higher ECV ($31.6 \pm 5.1$ vs $25.4 \pm 1.9$, $P < 0.001$; Table 3 and Fig. 2a), mainly driven by the cirrhosis patients with Child-Pugh class C (Table 3 and Fig. 2b). Furthermore, a significant correlation between Child-Pugh score and ECV was noted ($r = 0.564$, $P = 0.001$; Fig. 3). Even after adjusting for cardiac index, the correlation between ECV and Child-Pugh score remained significant ($r = 0.427$, $P = 0.019$). The pre-transplant native T2 values measured in 6 patients at the last stage of this study were within normal range in all 6 patients (100%), whereas pre-transplant ECV was more than 30.0% in 4/6 patients (66.7%) (Table 4).

### Changes in echocardiographic and CMR parameters 1 year after transplant

A total of 28 patients underwent transplant, of which four (14.3%) died after transplantation. Three patients died of sepsis-associated heart failure within 6 months after transplant, and 1 patient died of heart failure 9 months after transplant. Patients who died after transplant were older, and had a lower pre-transplant CMR cardiac index (Additional file 1: Tables S1-S3). Of the 24 patients who survived transplant, 19 patients underwent echocardiography, ECG, and CMR 1-year post-transplant. Five patients refused follow-up examinations 1 year after transplant. Pre- and post- transplant ECG, echocardiographic and CMR parameters of the 19 patients were compared (Table 5 and Fig. 4). ECV showed a significant decrease 1 year after transplant ($P < 0.001$; Fig. 4a). Both LV end-diastolic diameter on

### Table 1 Baseline clinical characteristics of 33 patients with liver cirrhosis

|                     | All $N = 33$ | Child-Pugh class A/B $N = 10$ | Child-Pugh class C $N = 23$ | $P$ value |
|---------------------|-------------|-------------------------------|-----------------------------|-----------|
| Age (years)         | 56.3 ± 9.9  | 58.8 ± 7.3                    | 55.3 ± 10.8                 | 0.355     |
| Male (n, %)         | 25 (75.8%)  | 9 (90.0%)                     | 16 (69.6%)                  | 0.208     |
| Systolic blood pressure (mmHg) | 113.47 ± 14.0 | 111.5 ± 7.6               | 114.4 ± 16.2                | 0.601     |
| Diastolic blood pressure (mmHg) | 66.3 ± 12.3   | 60.9 ± 9.0                   | 68.8 ± 12.9                 | 0.094     |
| Heart rate (min)    | 73.6 ± 15.7 | 63.3 ± 9.1                    | 78.0 ± 16.0                 | 0.002     |
| Cirrhosis etiology (n, %) |           |                               |                             | 0.296     |
| Viral               | 20 (60.6%)  | 8 (80.0%)                     | 12 (52.2%)                  |           |
| HBV                 | 17 (51.5%)  | 6 (60.0%)                     | 11 (47.8%)                  |           |
| HCV                 | 3 (9.1%)    | 2 (20.0%)                     | 1 (4.3%)                    |           |
| Alcoholic           | 9 (27.3%)   | 1 (10.0%)                     | 8 (34.8%)                   |           |
| Autoimmune hepatitis| 2 (6.1%)    | 0 (0%)                        | 2 (8.7%)                    |           |
| Cryptogenic         | 2 (6.1%)    | 1 (10.0%)                     | 1 (4.3%)                    |           |
| Child-Pugh score    | 9.8 ± 2.4   | 6.8 ± 1.3                     | 11.1 ± 1.2                  | $< 0.001$ |
| MELD score          | 18.8 ± 7.4  | 11.1 ± 2.1                    | 22.1 ± 6.3                  | $< 0.001$ |
| Underlying diseases (n, %) |           |                               |                             |           |
| Hypertension        | 8 (24.2%)   | 4 (40.0%)                     | 4 (17.4%)                   | 0.164     |
| Diabetes mellitus   | 9 (27.3%)   | 4 (40.0%)                     | 5 (21.7%)                   | 0.279     |
| Medication (n, %)   |             |                               |                             |           |
| Beta-blockers       | 8 (24.2%)   | 6 (60.0%)                     | 2 (8.7%)                    | 0.002     |
| Diuretics           | 17 (51.5%)  | 4 (40.0%)                     | 13 (56.5%)                  | 0.383     |
| ACEI/ARB            | 3 (9.1%)    | 2 (20%)                       | 1 (4.3%)                    | 0.151     |
| Laboratory examination |           |                               |                             |           |
| Hemoglobin (g/dL)   | 10.6 ± 1.6  | 11.4 ± 1.6                    | 10.2 ± 1.5                  | 0.050     |
| Creatinine (mg/dL)  | 0.9 ± 0.4   | 0.8 ± 0.2                     | 0.9 ± 0.4                   | 0.565     |
| Bilirubin (mg/dL)   | 7.5 ± 8.5   | 1.7 ± 0.6                     | 10.0 ± 9.1                  | $< 0.001$ |
| Albumin (g/dL)      | 2.9 ± 0.4   | 3.2 ± 0.4                     | 2.7 ± 0.4                   | 0.002     |
| PT (INR)            | 1.9 ± 1.0   | 1.3 ± 0.2                     | 2.1 ± 1.1                   | 0.001     |

Values are shown as number (%) or mean ± standard deviation

HBV hepatitis B virus, HCV hepatitis C virus, MELD the model for end stage liver disease, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, PT prothrombin time, INR international normalized ratio
echocardiography and LV EDV on CMR significantly decreased 1-year post-transplant (P = 0.003 and 0.001, respectively). Although CMR LVEF showed no significant changes 1-year post-transplant (P = 0.382), LV GLS (from −24.9 ± 2.4% to −20.6 ± 3.4%, P < 0.001; Fig. 4b) and GCS (from −28.4 ± 3.6% to −24.6 ± 4.2%, P = 0.011; Fig. 4c) on echocardiography significantly decreased 1 year after transplant. LV mass index by CMR showed a significant decrease 1 year after transplant, and LV concentricity by LV mass/LV EDV ratio showed a significant increase (Table 5 and Fig. 5). QTc interval also decreased (from 475 ± 41 msec to 429 ± 30 msec, P = 0.001; Fig. 4d). E/A ratio was significantly decreased 1-year post-transplant (from 1.2 ± 0.5 to 0.9 ± 0.3, P = 0.002). E/e′ ratio was significantly decreased, as well (11.0 ± 0.23 to 8.9 ± 2.9, P = 0.030).

Discussion

Hemodynamic adaptation in liver cirrhosis was first reported in 1953 [25]. Thereafter, cardiac dysfunction in
cirrhosis has gained increasing attention, leading to coin-
ing the term ‘cirrhotic cardiomyopathy’. Functional and
hemodynamic changes have been repeatedly described [4,
5, 26–28]; however, there has been a paucity of data re-
garding myocardial structural alterations in an in vivo set-
ing. Here, we adopted CMR to demonstrate myocardial
structural changes in transplant. CMR is best suited for
myocardial tissue characterization in vivo, thanks to its
unique LGE and T1 mapping techniques [12, 14, 22, 23].
Speckle-tracking echocardiography-derived GLS was also
assessed to sensitively detect LV systolic functional
changes, because it is known as the most sensitive and ac-
curate index for systolic function [29, 30].

The main findings of this study are summarized as follows
and in Fig. 6: First, ECV was significantly increased in cir-
rhosis patients and showed a positive correlation with cir-
rhosis severity (assessed by Child-Pugh score; Fig. 3).

Moreover, the QTc correlated with Child-Pugh score and
ECV. These findings support that cirrhosis severity, myocar-
dial structural changes, and myocardial electrical alterations
are closely linked to each other. Second, assessment of
resting LV diastolic function by echocardiography was im-
practical because almost half of cirrhosis patients (45.5%)
could not be conclusively categorised based on the current
guideline [19]. Finally, pre-transplant echocardiographic
GLS was significantly augmented at rest, which recovered to
the normal ranges 1 year after transplant. ECV and QTc
normalization was also observed 1 year after transplant.
Therefore, increased ECV and augmented GLS are consid-
ered two characteristic features of cirrhotic cardiomyopathy.

To the best of our knowledge, this is the first study to
evaluate myocardial structural and functional characteris-
tics before and after liver transplant using both CMR and
speckle-tracking echocardiography in cirrhosis patients.

### Table 3 Baseline cardiovascular magnetic resonance parameters

|                      | Healthy controls | Cirrhosis     | Child-Pugh class A/B | Child-Pugh class C | P value† | P value* |
|----------------------|------------------|---------------|----------------------|--------------------|----------|----------|
| N = 20               | N = 33           | N = 10        | N = 23               |                    |          |          |
| LVEF (%)             | 63.4 ± 6.4       | 67.8 ± 6.9    | 66.1 ± 6.5           | 68.5 ± 7.1         | 0.027    | 0.368    |
| LV EDV (mL)          | 135 ± 20         | 150 ± 47      | 153 ± 42             | 149 ± 50           | 0.101    | 0.811    |
| LV ESV (mL)          | 51 ± 16          | 49 ± 21       | 52 ± 18              | 48 ± 23            | 0.752    | 0.604    |
| Stroke volume (mL)   | 85 ± 15          | 100 ± 29      | 101 ± 28             | 99 ± 30            | 0.025    | 0.845    |
| Cardiac index (L/min)| 3.3 ± 0.7        | 4.3 ± 1.1     | 3.8 ± 1.0            | 4.5 ± 1.1          | 0.002    | 0.073    |
| LV mass index (g/m²) | 76.8 ± 13.0      | 70.7 ± 15.8   | 70.1 ± 13.0          | 71.0 ± 17.1        | 0.138    | 0.858    |
| LV mass/LV-EDV ratio | 0.9 ± 0.2        | 0.8 ± 0.3     | 0.8 ± 0.3            | 0.9 ± 0.2          | 0.126    | 0.875    |
| Presence of LGE      | 0 (0%)           | 1 (3.0%)      | 0 (0%)               | 1 (4.3%)           | 0.432    | 0.503    |
| Native T1 (msec)     | 1174 ± 65        | 1228 ± 79     | 1216 ± 60            | 1233 ± 87          | 0.001    | 0.584    |
| ECV (%)              | 25.4 ± 1.9       | 31.6 ± 5.1    | 27.2 ± 3.4           | 33.6 ± 4.4         | < 0.001  | 0.001    |

LVEF left ventricular ejection fraction, EDV end-diastolic volume, ESV end-systolic volume, LGE late gadolinium enhancement, ECV extracellular volume fraction
†P value between normal and all LC groups
*P value between Child-Pugh class A/B and Child-Pugh class C

Fig. 2 Diffuse myocardial fibrosis assessed by ECV in patients with liver cirrhosis (LC) and normal controls. a Extracellular volume (ECV) was significantly higher in cirrhosis patients. b Progressive increase in ECV was demonstrated from healthy controls to patients with Child-Pugh class C (P < 0.001)
Echocardiographic and electrophysiological components in the diagnosis of cirrhotic cardiomyopathy

Patients with cirrhosis experience a series of cardiovascular changes, including splanchnic arterial vasodilation with associated reduced systemic vascular resistance, neurohumoral axes dysfunction, and myocardial functional/electrophysiological changes. Apart from redistribution of circulating blood volume to the splanchnic bed, reduced systemic vascular resistance results in reduced central blood volume, subsequently leading to a resting hyper-dynamic syndrome. Thus, the resting hyper-dynamic state in cirrhosis by the hyper-contractile LV is considered an appropriate adaptive process to compensate for reduced central blood volume [1, 31]. This study also noted that LVEF was significantly greater in cirrhosis patients, which is supported by significantly increased echocardiographic GLS pre-transplant. No patient showed an LVEF < 55%, suggesting that the absolute number of resting LVEF itself is less clinically helpful to define cirrhotic cardiomyopathy. LV stain is more sensitive than LVEF to subtle changes in LV myocardial performance [29, 30]. We found that GCS in cirrhosis patients was not different from that in the normal controls, whereas GLS showed significant differences between the two groups. This finding suggests that GLS better reflects subtle changes in LV systolic performance, as suggested previously [29, 30, 32, 33].

LV diastolic dysfunction at rest was proposed as a diagnostic and supportive criterion for cirrhotic cardiomyopathy [2]. In this study, LAVI was greater in cirrhosis, indicating prolonged LV diastolic dysfunction in cirrhosis patients. Although E/e’ ratio was significantly higher in cirrhosis patients, it fell between 8 and 15, borderline values that cannot be used for clear differentiation between normal and increased LV filling pressure [34]. However, elevated LV filling pressure seemed to be present because E/A ratio was also > 1 in cirrhosis patients [35]. However, the significant overlap of LAVI and even E/e’ ratio between cirrhosis patients and the normal controls should be emphasized (Fig. 1b and c). Any cut-off value of LAVI or E/e’ ratio differentiating the two groups could not be suggested. Besides, LV diastolic function was not effectively categorised in approximately 50% of cirrhosis patients, suggesting that LV diastolic function assessment with resting echocardiography is neither practical nor sensitive approach for the diagnosis of cirrhotic cardiomyopathy. This observation makes sense given that overt structural changes in the LV are not a prerequisite for LV diastolic dysfunction development; simply, the aging process could lead to this change [35]. Although dobutamine or exercise stress echocardiography was suggested as alternative modalities to reveal subclinical LV systolic/diastolic dysfunction [28], a

Table 4 Individual patient pre-transplant native T2 value and ECV

| Patient | Pre-transplant native T2 | Pre-transplant ECV |
|---------|--------------------------|--------------------|
| 1       | 35.71                    | 24.5%              |
| 2       | 44.41                    | 34.6%              |
| 3       | 39.11                    | 27.8%              |
| 4       | 44.72                    | 32.6%              |
| 5       | 35.71                    | 39.8%              |
| 6       | 36.48                    | 43.0%              |

ECV extracellular volume fraction

Table 5 Changes in electrocardiographic, echocardiographic and CMR parameters in patients undergoing transplant

|                  | Pre-transplant | 1 year post-transplant | P value |
|------------------|----------------|------------------------|---------|
| Echocardiography |                |                        |         |
| LVEF (%)         | 65.8 ± 5.0     | 62.5 ± 4.9              | 0.035   |
| LV EDD (mm)      | 49.5 ± 4.7     | 46.0 ± 5.1              | 0.003   |
| LV ESD (mm)      | 28.7 ± 3.9     | 27.9 ± 4.0              | 0.465   |
| GLS (%)          | −24.9 ± 2.4    | −20.6 ± 3.4             | <0.001  |
| GCS (%)          | −28.4 ± 3.6    | −24.6 ± 4.2             | 0.011   |
| E/A ratio        | 1.18 ± 0.51    | 0.85 ± 0.27             | 0.002   |
| E/e’ ratio       | 11.0 ± 0.23    | 8.9 ± 2.9               | 0.030   |
| CMR              |                |                        |         |
| LV EDV (mL)      | 167 ± 48       | 130 ± 30                | 0.001   |
| LV ESV (mL)      | 57 ± 22        | 48 ± 17                 | 0.102   |
| LVEF (%)         | 66.8 ± 6.8     | 65.1 ± 6.5              | 0.382   |
| LV mass index (g/m²) | 65.2 ± 9.3   | 59.5 ± 8.2              | 0.001   |
| LV mass/LV-EDV ratio | 0.7 ± 0.3   | 0.8 ± 0.1               | 0.028   |
| Native T1 (msec) | 1206 ± 72      | 1173 ± 73               | 0.121   |
| ECV (%)          | 30.9 ± 4.5     | 25.4 ± 2.6              | <0.001  |
| Electrocardiogram|                |                        |         |
| QTc interval (msec) | 475 ± 41     | 429 ± 30                | 0.001   |

Abbreviations as in Tables 2 and 3

Fig. 3 Relationship between the degree of diffuse myocardial fibrosis and cirrhosis severity. ECV denotes extracellular volume fraction
definite diagnosis of cirrhotic cardiomyopathy remains challenging [2, 6].

QTc prolongation was also suggested as a component of cirrhotic cardiomyopathy [27, 36]. Although the mechanisms are unclear, cirrhosis progression seems to be related to prolonged QTc, given that Child-Pugh score showed a positive correlation with QTc interval. Furthermore, we found that liver transplant normalized QTc prolongation 1 year after transplant (Fig. 4d), thereby showing a close relationship between the two. Thus, QTc prolongation should alert physicians for the possibility of cirrhotic cardiomyopathy; subsequently, efforts to identify other evidences of cirrhotic cardiomyopathy should be made.

Myocardial structural alterations in cirrhosis

Data regarding myocardial histopathological changes in cirrhosis are limited [37]. Most of earlier investigations were conducted in an autopsy setting of alcoholic etiology, and thus whether the findings are attributable to alcoholic cardiomyopathy and whether similar findings could be anticipated in an in vivo setting remain to be established. CMR is best suited for this purpose with its unique ability to characterise myocardial tissues. LGE represents irreversible replacement fibrosis, while ECV represents reversible DMF [10, 13]. As myocardial fibrosis is associated with cardiac hypertrophy and a stiff, noncompliant LV [38], application of these two novel CMR techniques is clinically relevant for the indirect assessment of LV compliance or diastolic property. In this study, irreversible LGE was observed only in one cirrhosis patient. Absence of coronary artery disease on pre-operative computed tomographic or invasive coronary angiography excluded the possibility of coronary disease in all patients. On the other hand, we observed a significant increment in ECV in cirrhosis, implying myocardial extracellular volume expansion. Additionally, we noted a significant relationship between ECV and cirrhosis severity. All of these findings support the earlier observation by Wiese et al. (i.e., ECV increased in cirrhosis patients) [8] and the concept of the heart-liver interaction [4, 39]. These observations highlight that an increased ECV in cirrhosis signifies real myocardial structural changes, thereby potentially representing a
structural component of cirrhotic cardiomyopathy. This is of diagnostic value because current definition of cirrhotic cardiomyopathy includes only functional, hemodynamic, and electrocardiographic alterations, all of which are expected as secondary phenomena following structural alterations. Of note, native T1 value did not change significantly 1-year post-transplant, which was in clear contrast to ECV. This may be because native T1 value can be more affected than ECV by factors other than DMF. Thus, assessment of ECV is preferred to native T1 value to reliably detect myocardial changes in cirrhosis. The mechanism underlying an increased ECV is unclear. One possibility is that, in patients with cirrhosis, effective circulatory volume decreases, as portal hypertension progresses, and subsequently renin-angiotensin aldosterone system is stimulated [40]. Given that the renin-angiotensin aldosterone system is involved in chronic tissue damage and diverse organ dysfunction including myocardium [41], it is possible that DMF in cirrhosis is likely to be related to the activation of renin-angiotensin aldosterone system.

The interpretation that increased ECV in cirrhosis represents DMF may be debatable because increased intravascular volume can expand myocardial extracellular space, thereby resulting in an increased ECV. However, as cirrhosis progresses, redistribution of blood volume occurs with a decrease in the central circulation (i.e. central hypovolemia) and an increase of blood volume in splanchnic bed [1]. In this setting, increased myocardial intravascular volume is unlikely to occur. Moreover, the observation of a stepwise increase in ECV from healthy subjects, Child-Pugh class A/B, to Child-Pugh class C does not support the hypothesis that increased intravascular volume may be responsible for increased ECV. Pathologic data also suggests that DMF should be major myocardial structural changes in cirrhosis; Lunseth and colleagues found delicate DMF in 99 autopsied cirrhosis cases [9]. They described that the interposition of delicate fibrous tissues was frequently noted in the gap caused by transversely ruptured muscle fibers, however exudation or edema was present in only two cases [9]. Additionally, a previous study demonstrated that patients with myocardial edema showed decreased GLS regardless of LVEF [42]. Furthermore, we observed that the pre-transplant native T2 values assessed in 6 patients were all within normal ranges. Taken together, it is highly likely that increased ECV on CMR in cirrhosis patients predominantly represents DMF.

**Transplant-induced structural, functional, and electrocardiographic changes**

Liver transplantation is the only curative treatment and has been believed to reverse structural, hemodynamic,
and functional cardiac alterations in cirrhosis. However, only two prospective studies investigated transplant-induced cardiac changes. In the first study, 19 patients were evaluated with echocardiography before and 6 to 12 months after transplant. The authors found that transplant resulted in LV wall thickness regression, and a decrease in cardiac index and LVEF, but no change in LV diastolic function indexes [26]. The second study evaluated 40 patients with echocardiography before and 3 months after transplant. They observed LV diastolic function deterioration [43]. The main discrepancy between the two studies is regarding LV diastolic function, which implies practical difficulties in LV diastolic function assessment with echocardiography. Although echocardiography is currently the best non-invasive tool [19, 35], echocardiographic transmitral inflow velocities are difficult to interpret in the setting of LV load changes such as in transplantation [44]. Recognition of this limitation led us to focus on the hemodynamic, systolic functional, and structural changes in the LV. Interestingly, echocardiographic GLS in cirrhosis was significantly augmented pre-transplant, and normalized 1-year post-transplant. Furthermore, a change in GLS was accompanied by a significant ECV reduction and QTc normalization (Table 5).

Augmented GLS at rest in cirrhosis could be explained by the resting recruitment of LV contractile reserve to maintain hyper-dynamic circulation [31]. Resting recruitment of LV contractile reserve is potentially associated with a blunted inotropic response to physical or pharmacological stress that is previously described as a characteristic component of cirrhotic cardiomyopathy. Augmented GLS and increased ECV pre-transplant were normalized 1-year post-transplant, suggesting that GLS and ECV assessment could provide a good opportunity to sensitively and early detect transplant-induced minute changes in LV ultrastructure as well as systolic function. Interestingly, despite limited number of patients analysed, elevated ECV pre-transplant was fully reversible 1-year post-transplant in all cirrhosis patients. Thus, ECV estimation would not be required to confirm the restoration of myocardial health post-transplant.

We observed a stepwise increase in ECV from healthy subjects, Child-Pugh class A/B, to Child-Pugh class C, suggesting that ECV quantification can be clinically used to track myocardial health in relation to cirrhosis severity. Detection of this unique cardiomyopathy pre-transplant is clinically relevant and important given that up to 25% of cirrhosis patients were reported to experience cardiac death after transplant [1]. Of note, however, statistical significance was not achieved between the normal controls and cirrhosis patients with Child-Pugh class A/B, suggesting that early detection with CMR alone may be clinically challenging even if myocardial alteration begins at the early stage of cirrhosis. Further efforts should be made to more sensitively detect early stage of DMF in cirrhosis patients.

**Study limitations**
Firstly, patients were enrolled in a prospective manner, but we had to exclude patients who could not undergo CMR, i.e. poor renal function or patients with acute clinical deterioration. Thus, our results could not be generalized to all terminally decompensated cirrhosis patients. Secondly, we did not demonstrate potential associations between CMR findings and long-term clinical outcomes. Finally, this study cannot provide definite clinical management directions to reduce the risk of cardiovascular events peri-operatively.

**Conclusions**
Myocardial extracellular expansion with augmented resting LV systolic function was a characteristic finding in cirrhotic cardiomyopathy. This cardiac change was reversible 1 year after liver transplantation, suggesting that hepatic decompensation itself should be a culprit for the cause of the observed myocardial structural and functional changes. Thus, myocardial extracellular expansion represents a structural component of myocardial change in cirrhosis.

**Supplementary information**
Supplementary information accompanies this paper at https://doi.org/10.1186/s12968-020-00622-2.

**Abbreviations**
CMR: Cardiovascular magnetic resonance; DMF: Diffuse myocardial fibrosis; ECG: Electrocardiogram; ECV: Extracellular volume fraction; EDV: End-diastolic volume; ESV: End-systolic volume; GCS: Global circumferential strain; GLS: Global longitudinal strain; LA: Left atrium/left atrial; LAVI: Left atrial volume index; LGE: Late gadolinium enhancement; LV: Left ventricle/left ventricular; LVEF: Left ventricular ejection fraction; LVMi: Left ventricular mass index; QTc: Corrected QT interval.

**Acknowledgements**
Not applicable.

**Authors’ contributions**
Hyue Mee Kim: study concept and design, acquisition of data, analysis and interpretation of data, drafting manuscript; Hyung-Kwan Kim: study concept and design, acquisition of data, interpretation of data, drafting manuscript, study supervision; Jeong-Hoon Lee: study concept and design, interpretation of data, critical revision of the manuscript for important intellectual content; Yun Bin Lee, Eun-Ah Park, and Dae-Won Sohn: critical revision of the manuscript for important intellectual content and statistical analysis. The author(s) read and approved the final manuscript.
Funding
This study was supported by the grant of CJ healthcare 2016 research fund.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study design was approved by the local ethics committee (Seoul National University Hospital) and was conducted according to the Declaration of Helsinki.

Consent for publication
Written informed consent was obtained from all study participants.

Competing interests
Dr. Hyung-Kwan Kim reports research grants from Actelion, Handok Pharmaceuticals, Dae-Woong Pharmaceuticals, and Norvatis. Dr. Jung-Hwan Yoon reports research grants from Bayer HealthCare Pharmaceuticals and AstraZeneca, and Dr. Yoon Jun Kim, research grants from BTG, Bayer HealthCare Pharmaceuticals, Ono, AstraZeneca, Roche, LG Life Science, and Bristol-Myers Squibb, lecture fees from Bayer HealthCare Pharmaceuticals and Gilead Science, and serving as an advisory board member or consultant of Gilead Science, Bayer HealthCare Pharmaceuticals, Ono, and AbbVie. All other authors report no conflict of interest.

Author details
1Division of Cardiology, Department of Internal Medicine and Cardiovascular Center, Section of Cardiovascular Imaging, Seoul National University Hospital, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea. 2Division of Cardiology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, South Korea. 3Division of Gastroenterology, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, South Korea. 4Department of Radiology, Seoul National University Hospital, Seoul, South Korea.

Received: 13 June 2019 Accepted: 31 March 2020

Published online: 23 April 2020

References
1. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol. 2010;56(7):539–49.
2. Moller S, Hove JD, Diven X, Bendsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol. 2013;167(4):1101–8.
3. Karagiannis D, Papathereodoris G, Vlachogiannakos J. Recent advances in cirrhotic cardiomyopathy. Dig Dis Sci. 2015;60(5):1141–51.
4. Moller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34(6):3804–11.
5. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56(6):869–75.
6. Ripol C, Catalina MV, Yotti R, Olmedilla L, Perez-Pena J, Lo Iacono O, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation. 2008;85(12):1766–72.
7. Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98(2):178–81.
8. Wiese S, Hove J, Mo S, Moukereje RP, Petersen CL, Vester-Andersen MK, et al. Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome. Liver Int. 2018;38(9):1614–23.
9. Lunseth JH, Olmstead EG, Abbood F. A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. AMA Arch Intern Med. 1958;102(3):405–13.
10. Puntmann VO, Peter E, Chandakshahkar Y, Nagel E. T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res. 2016;119(2):277–99.
11. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012;5(9):897–907.
12. Lee SP, Lee W, Lee JM, Park EA, Kim HK, Kim YJ, et al. Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology. 2015;274(2):539–69.
13. Nakamori S, Dohi K, Ishida M, Goto Y, Imanaka-Yoshida K, Omori T, et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc Imaging. 2018;11(1):48–59.
14. Lin L, Li X, Feng J, Shen KN, Tian Z, Sun J, et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiac magnetic resonance imaging in patients with light chain amyloidosis. J Cardiovasc Magn Reson. 2018;20(1):2.
15. Aube C, Oberti F, Koral N, Namour MA, Loisel D, Tanguy JY, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol. 1999;30(3):472–8.
16. Ben zigotti A, Ashkenazi E, Reverter E, Abraldes JG, Bosch J. Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Dis Markers. 2011;31(3):129–38.
17. Galani S, Gramantieri L, Ventura L, Piscaglia F, Siringo D, D’Enrico A, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997;27(6):979–85.
18. Lang RM, Badano LP, Mor-Avi V, Alfaiato J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(11):1–39.e14.
19. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.
20. Voigt JU, Piedrazezi G, Lystrup SF, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D-speckle tracking echocardiography: consensus document of the EACVI/AASE/Industry task force to standardize deformation imaging. J Am Soc Echocardiogr. 2015;28(2):183–93.
21. Anzulescu MS, De Craene M, Langet H, Pasquet A, Vancraeynest D, Pouleur AC, et al. Myocardial strain imaging: review of general principles, validation, and sources of discrepancies. Eur Heart J Cardiovasc Imaging. 2019;20(8):655–9.
22. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized P. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008;10:35.
23. Mesroghli DR, Radjenovic A, Kozere S, Higgins DM, Sivananthan MU, Ridgway JP. Modified look-locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52(1):141–6.
24. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiac magnetic resonance imaging for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122(2):138–44.
25. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest. 1953;32(10):1025–33.
26. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista E, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42(1):68–74.
27. Moller S, Henifret JH. Cardiovascular complications of cirrhosis. Postgrad Med J. 2009;85(999):44–54.
28. Kim MY, Baik SK, Won CS, Park HI, Jeon HK, Hong HJ, et al. Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Korean J Hepatol. 2010;16(4):376–82.
29. Collier P, Phelan D, Klein A. A test in context: myocardial strain measured by speckle-tracking echocardiography. J Am Coll Cardiol. 2017;69(8):1043–56.
30. Smiseth OA, Toph H, Opdahl A, Haugaa KH, Urheim S. Myocardial strain imaging how useful is it in clinical decision making? Eur Heart J. 2016;37(15):1196–207.
31. Bernardi M, Fornale L, Di Marco C, Trevianni F, Baraldi M, Gasbarrini A, et al. Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol. 1995;22(3):309–18.
32. Lumens J, Prinzen FW, Delhaas T. Longitudinal strain: "think globally, track locally". JACC Cardiovasc Imaging. 2015;8(12):1360–3.

33. Diao KY, Yang ZG, Ma M, He Y, Zhao Q, Liu X, et al. The diagnostic value of global longitudinal strain (GLS) on myocardial infarction size by echocardiography: a systematic review and meta-analysis. Sci Rep. 2017;7(1):10082.

34. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000;102(15):1788–94.

35. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol. 1997;30(2):474–80.

36. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol. 1997;30(2):474–80.

37. Vaideeswar P, Chaudhari C, Rane S, Gondhalekar J, Dandekar S. Cardiac pathology in chronic alcoholics: a preliminary study. J Postgrad Med. 2014;60(4):372–6.

38. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 1995;91(1):161–70.

39. Moller S, Dumcke CW, Krag A. The heart and the liver. Expert Rev Gastroenterol Hepatol. 2009;3(1):51–64.

40. Di Pascoli M, La Mura V. Renin-angiotensin-aldosterone system in cirrhosis: There’s room to try! Dig Liver Dis. 2019;51(2):297–8.

41. Mewton N, Liu CY, Croissille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891–903.

42. Logstrup BB, Nielsen JM, Kim WY, Poulsen SH. Myocardial oedema in acute myocarditis detected by echocardiographic 2D myocardial deformation analysis. Eur Heart J Cardiovasc Imaging. 2016;17(9):1018–26.

43. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl. 2002;8(8):690–700.

44. Choong CY, Heirmann HC, Weyman AE, Fifer MA. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans. J Am Coll Cardiol. 1987;10(4):800–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.